These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24726430)

  • 21. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple regions of alpha-synuclein are associated with Parkinson's disease.
    Mueller JC; Fuchs J; Hofer A; Zimprich A; Lichtner P; Illig T; Berg D; Wüllner U; Meitinger T; Gasser T
    Ann Neurol; 2005 Apr; 57(4):535-41. PubMed ID: 15786467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-synuclein and Parkinson's disease.
    Recchia A; Debetto P; Negro A; Guidolin D; Skaper SD; Giusti P
    FASEB J; 2004 Apr; 18(6):617-26. PubMed ID: 15054084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycobacterial immunomodulation and viral manipulation of neuronal copper efflux in the setting of sporadic Parkinson's disease: A multi - hit, outside - in hypothesis of its pathogenesis.
    Vavougios GD
    Med Hypotheses; 2020 Mar; 136():109505. PubMed ID: 31765844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
    Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
    Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
    Ulusoy A; Decressac M; Kirik D; Björklund A
    Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein.
    Woulfe J; Gray MT; Ganesh MS; Middeldorp JM
    Neurol Neuroimmunol Neuroinflamm; 2016 Aug; 3(4):e239. PubMed ID: 27218119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro.
    Ghosh D; Mondal M; Mohite GM; Singh PK; Ranjan P; Anoop A; Ghosh S; Jha NN; Kumar A; Maji SK
    Biochemistry; 2013 Oct; 52(40):6925-7. PubMed ID: 24047453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
    Li B; Zhang Y; Yuan Y; Chen N
    Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring Braak's Hypothesis of Parkinson's Disease.
    Rietdijk CD; Perez-Pardo P; Garssen J; van Wezel RJ; Kraneveld AD
    Front Neurol; 2017; 8():37. PubMed ID: 28243222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease.
    Caggiu E; Paulus K; Galleri G; Arru G; Manetti R; Sechi GP; Sechi LA
    J Neuroimmunol; 2017 Sep; 310():26-31. PubMed ID: 28778441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration.
    Friedland RP
    J Alzheimers Dis; 2015; 45(2):349-62. PubMed ID: 25589730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease.
    Schindlbeck KA; Eidelberg D
    Lancet Neurol; 2019 Aug; 18(8):713-714. PubMed ID: 31229471
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinson's disease; the hibernating spore hypothesis.
    Berstad K; Berstad JER
    Med Hypotheses; 2017 Jul; 104():48-53. PubMed ID: 28673590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal dysfunction in Parkinson's disease.
    Fasano A; Visanji NP; Liu LW; Lang AE; Pfeiffer RF
    Lancet Neurol; 2015 Jun; 14(6):625-39. PubMed ID: 25987282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Where does Parkinson's disease start?].
    Zarranz Imirizaldu JJ
    An R Acad Nac Med (Madr); 2011; 128(2):303-12; discussion 312-6. PubMed ID: 23350332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.